Lung Cancer

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses considerations for managing immune-related adverse events in patients with non–small cell lung cancer.

Sukhmani Padda, MD, assistant professor of medicine, Stanford University Medical Center, member, Stanford Cancer Institute, discusses novel combinations in the treatment of patients with EGFR-positive non–small cell lung cancer.

The European Commission has approved and granted marketing authorization to the frontline combination of atezolizumab, bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small cell lung cancer.

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the utility of liquid biopsies in lung cancer.

Mohammad Jahanzeb, MD, shares the challenges of real-world eligibility for immunotherapy in lung cancer and beyond.

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses unmet needs for immunotherapy in the treatment of patients with non–small cell lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.

Michael D. Mix, MD, assistant professor of radiation oncology at Upstate University Hospital, discusses the use of local consolidative therapy in patients with oligometastatic non–small cell lung cancer (NSCLC).

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of lorlatinib for the treatment of adult patients with ALK-positive advanced non–small cell lung cancer whose disease has progressed after alectinib or ceritinib as the first ALK TKI, or crizotinib and at least one other ALK TKI.

An increasing amount of evidence shows that a proportion of patients with cancer found to have low-volume metastases at diagnosis see meaningful benefit from aggressive local therapy. Equally important, there have been no meaningful reductions in reported quality of life among patients receiving intensive local therapy, and a small percentage of patients appear to be cured with this strategy.

Mohammad Jahanzeb, MD, professor of clinical medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses immunotherapy in the treatment of elderly patients with non–small cell lung cancer.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

Robert J. Cerfolio, MD, director of the Lung Cancer Center, chief of clinical thoracic surgery, NYU Langone’s Perlmutter Cancer Center, discusses the role of surgery in lung cancer.

Janakiraman Subramanian, MD, a medical oncologist and director of thoracic oncology and director of the Center for Precision Medicine at Saint Luke’s Cancer Institute, discusses tumor biology in lung cancer.